Antidepressants in Pregnancy Do Not Affect Child Neurodevelopment

Only crude associations seen between risk for neurodevelopmental outcomes and exposure to antidepressants

pregnancy pregnant pill medication water
Adobe Stock

TUESDAY, Oct. 4, 2022 (HealthDay News) -- Antidepressant use in pregnancy is not associated with an increased risk for neurodevelopmental disorders in children, according to a study published online Oct. 3 in JAMA Internal Medicine.

Elizabeth A. Suarez, M.P.H., Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the association between antidepressant use in pregnancy and neurodevelopmental outcomes in children using data from cohorts of publicly and privately insured pregnant individuals and their children. A total of 1.93 million pregnancies in the Medicaid Analytic eXtract and 1.25 million pregnancies in the IBM MarketScan Research Database were recorded. Children were followed from birth for a maximum of 14 years. Data were included for 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies.

The researchers found that the crude results suggested up to a doubling in the risk for neurodevelopmental outcomes in association with exposure to antidepressants; however, in fully adjusted analyses, no association was observed. Comparing antidepressant-exposed with unexposed siblings, the hazard ratios (95 percent confidence intervals) were 0.97 (0.88 to 1.06), 0.86 (0.60 to 1.23), 0.94 (0.81 to 1.08), 0.77 (0.42 to 1.39), 1.01 (0.88 to 1.16), 0.79 (0.54 to 1.17), 1.00 (0.45 to 2.22), and 0.95 (0.80 to 1.12) for any neurodevelopmental disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, specific learning disorders, developmental speech/language disorders, developmental coordination disorder, intellectual disability, and behavioral disorders, respectively.

"Antidepressant exposure during pregnancy could be an important marker for early screening and intervention in children, with the goal of improving outcomes for neurodevelopmental disorders," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on October 04, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ